Drugs by condition
Drugs approved for uterine fibroids
Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
2
Still marketed, NDA or BLA
Drug classes
2
Novel drugs
0
New molecular entities and new biologics
In development
1
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for uterine fibroids.
- Myfembree (Estradiol, Norethindrone Acetate, Relugolix) · Sumitomo Pharma Am May 26, 2021
- Oriahnn (Copackaged) (Elagolix Sodium,Estradiol,Norethindrone Acetate, Elagolix Sodium) · Abbvie May 29, 2020
All approved drugs for uterine fibroids, by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 7 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
Gonadotropin Releasing Hormone Receptor Antagonist (1)
- Myfembree Estradiol, Norethindrone Acetate, Relugolix · Sumitomo Pharma Am · 2021
Class not listed in FDA's data (1)
- Oriahnn (Copackaged) Elagolix Sodium,Estradiol,Norethindrone Acetate, Elagolix Sodium · Abbvie · 2020
Drugs in development for uterine fibroids
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- KLH-2109Phase 32 trials
JW Pharmaceutical · Menorrhagia, Uterine Fibroids, Endometriosis
More on uterine fibroids: recruiting trials · published research
Related in endocrinology and women's health: Hypothyroidism · Osteoporosis · Menopause symptoms · Endometriosis · Birth control · Low testosterone · Growth hormone deficiency · Acromegaly · Cushing's syndrome
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.